Michael C. Mancini,
VP, Research & Development
Spectropath, Inc.
时间：2014年7月28日14：00
地点：科学楼902室
Abstract:
Cancer describes many diseases which share a common attribute: rapid and uncontrolled cell growth, with the ability to spread throughout the body. Cancer is difficult to treat in part due to the difficulty in detecting the disease before it has spread throughout the body, and in part due to the diversity in cancer types. Once cancer is detected, surgery is often the treatment of choice for accessible solid-mass tumors: it is intuitive that if the entirety of a tumor can be removed from the patient before metastasis can occur, the patient will be cured. Although preoperative imaging and diagnostics can pinpoint the location of a tumor, there are few intraoperative options for locating a tumor during surgery (beyond the surgeon's senses of touch and sight). Once a tumor is removed from the patient, this surgical specimen is then analyzed by pathologists to confirm that the entire tumor mass has been removed. Due to time and cost constraints, the entire surgical specimen cannot be examined in detail: pathologists must locate the areas of a surgical specimen most worthwhile for detailed examination (presently based on gross appearance and experience of the pathologist). The use of optical imaging systems, along with a tumor-specific contrast agent, can greatly increase the effectiveness of both surgeons and pathologists in treating cancer. This talk will examine the growing field of image-guided medicine as applied to cancer surgery. We will review current and emerging technologies for image-guided surgery, and discuss future directions that are likely for the field.
Bio:
Michael Mancini is currently the vice-president for research and development at Spectropath, a startup company based in Atlanta, Georgia, USA. Spectropath focuses on commercializing novel imaging systems for medical applications. The first commercial product is an image-guided system for cancer surgery, and following the release of this product, Spectropath will expand it's imaging technology to other medical problem areas. Prior to joining Spectropath, Michael was a graduate student in the biomedical engineering program at Georgia Tech and Emory Univeristy; part of his graduate research was in image-guided surgery and is an essential component of the Spectropath technology platform. Michael's scientific interests are in nanotechnology and biomedical optics. He holds a Ph.D. from Georgia Tech and Emory University, and a B.S. in biomedical engineering, with distinction, from the University of Rochester.